Back to the Virtual Exhibit Hall


Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the development and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit to see the full Prescribing Information and learn more.



Judy Thropp

Pittsburgh Territory Business Manager

Rigel Pharmaceuticals

716-474-5987 cell phone










Patient Website

BJH Publication


TAVALISSE Patient Onboarding Materials


Check out “Tava Itp-20213-Tavalisse Clinical Data Compendium Kol Video” from Rigel Pharmaceuticals, Inc. on Vimeo.

The video is available for your viewing pleasure at